Can two antibodies flush out hidden HIV? new trial aims to reduce lifelong pills

This early-stage study tests whether two experimental antibodies (3BNC117-LS and 10-1074-LS) are safe and can reduce the hidden HIV reservoirs that persist even when standard antiretroviral therapy (ART) keeps the virus undetectable. About 105 adults with HIV who are stable on ART will receive three infusions of the antibodies or a placebo over 40 weeks. The goal is to see if these antibodies can lower the number of infected cells, potentially reducing the need for lifelong daily medication.